Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Opioid-Induced Respiratory Depression, P...
Phase Not Applicable
Enrollment 300
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate whether quantitative pupillometry measurements can be used to identify children at risk for postoperative opioid-induced respiratory depression (OIRD) following tonsillectomy. Opioid-induced respiratory depression is a serious and potentially life-threatening complication that can occur after surgery, and current monitoring approaches are limited in their ability to predict which patients are at highest risk. In this prospective observational cohort study, approximately 300 pediatric patients undergoing tonsillectomy will undergo non-invasive pupillometry measurements at defined perioperative time points, including preoperative, intraoperative, and postoperative periods. Pupillometry measurements will be collected using a commercially available, FDA-regulated infrared pupillometer. These measurements will include pupil size, constriction and dilation velocities, and latency in response to light stimulation. Pupillometry data will be collected for research purposes only and will not be used to guide clinical care or treatment decisions. Standard clinical care will not be altered as part of this study. Clinical outcomes, including the occurrence of postoperative opioid-induced respiratory depression, opioid use, sedation levels, pain scores, and other postoperative events, will be recorded from the medical record. The goal of this study is to evaluate the relationship between pupillary response patterns and the occurrence of postoperative respiratory depression, and to support the development of predictive models that may improve early identification of patients at risk for opioid-related adverse events.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Infrared Pupillometry — Non-invasive pupillometry measurements will be performed using a commercially available, FDA-regulated infrared pupillometer. Measurements will be collected at predefined perioperative time points for research purposes only and will not be used to guide clinical care.

Primary Outcomes

  • Occurrence of Postoperative Opioid-Induced Respiratory Depression (From arrival in post-anesthesia care unit (PACU) through PACU discharge (up to 4 hours postoperatively))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-04
Completion: 2027-04-30
Eligibility
Age: 3 Years and older
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NeurOptics Inc
Collaborators: National Institute on Drug Abuse (NIDA), University of Pittsburgh Medical Center, University of California, San Francisco
Principal Investigators:
  • Jeffrey W Oliver, PhD (STUDY_DIRECTOR) - NeurOptics Inc
Contact Information
Study Contact:
Alisha Maslanka, BS, CCRC
412-491-2748
alisha.maslanka@chp.edu
Senthilkumar Sadhasivam, MD
513-253-4684
sadhasivams@upmc.edu
Rachel Eshima McKay, MD
415-310-7722
Rachel.Eshima@ucsf.edu
UCSF Benioff Children's Hospital
Interventions
  • Device: Infrared Pupillometry — Non-invasive pupillometry measurements will be performed using a commercially available, FDA-regulated infrared pupillometer. Measurements will be collected at predefined perioperative time points for research purposes only and will not be used to guide clinical care.
Study Locations (2 sites)
UCSF Benioff Children's Hospital, San Francisco, California 94158 United States
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Age 3 to less than 18 years * Scheduled to undergo tonsillectomy with or without adenoidectomy * Planned postoperative recovery in a monitored clinical setting (e.g., post-anesthesia care unit) * Ability to obtain informed consent from parent or legal guardian and assent from the participant when developmentally appropriate Exclusion Criteria: * Known neurologic or ophthalmologic conditions that may affect pupillary function * Use of medications known to significantly alter pupillary response outside of standard perioperative care * Inability to obtain adequate pupillometry measurements (e.g., due to eye injury or inability to safely perform measurement) * Patients not receiving opioids as part of perioperative care * Any condition that, in the opinion of the investigator, would interfere with study participation or data interpretation
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase NA
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies whether a healthy living intervention (HLI), with or without a physical activity intervention (PAI), helps maintain the ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment. Early detection and enhanced therapies for breast cancer have improved 5-year cancer-related survival rates. Unfortunately, many breast cancer survivors are at high risk for long-term exercise intolerance, decreased heart health, and lower quality of life following chemotherapy. Currently, there are no effective therapies to help patients maintain these areas throughout chemotherapy. The HLI in this study includes virtual health education classes, which provide useful information on topics like proper nutrition, managing stress, and sleep practices. This may help patients understand the importance of living a healthy lifestyle during chemotherapy. The PAI in this study consists of virtual exercise sessions personalized to the needs of the patient, which may make it easier for patients to stay active during chemotherapy. HLI with PAI may be a more effective way to help maintain ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Exercise Intervention — Attend virtual personalized exercise sessions
  • Other: Educational Intervention — Attend organized health workshops
  • Other: Supportive Care — Receive Fitbit device, resistance bands, and/or loaner tablet
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Magnetic Resonance Imaging — Undergo CMR
  • Procedure: Magnetic Resonance Imaging — Undergo ExeCMR
  • Other: Questionnaire Administration — Ancillary studies
  • Procedure: Accelerometry — Ancillary Studies

Primary Outcomes

  • Peak oxygen consumption (VO2) (At baseline and 24 weeks)
  • Left ventricular ejection fraction (LVEF) (At baseline and 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-27
Completion: 2030-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Principal Investigators:
  • Glenn Lesser, MD (STUDY_CHAIR) - Wake Forest University Health Sciences
Contact Information
Study Contact:
Karen Craver, MT, MHA
336-716-0891
NCORP@wfusm.edu
Glenn Lesser, MD
336-716-0891
ncorp@wfusm.edu
Wake Forest NCORP RB
Karen Craver, MHA
336-716-0891
ncorp@wfusm.edu
Wake Forest NCORP RB
Interventions
  • Other: Exercise Intervention — Attend virtual personalized exercise sessions
  • Other: Educational Intervention — Attend organized health workshops
  • Other: Supportive Care — Receive Fitbit device, resistance bands, and/or loaner tablet
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Magnetic Resonance Imaging — Undergo CMR
Study Locations (2 sites)
Wake Forest NCORP RB, Winston-Salem, North Carolina 27157 United States
Wake Forest NCORP Research Base, Winston-Salem, North Carolina 27157 United States
Eligibility Criteria
Inclusion Criteria: * Stage I-III breast cancer (including inflammatory and newly diagnosed, or locally recurrent \[if prior treatment received ≥ 2 years prior\] but not metastatic breast cancer being treated with curative intent). All molecular subtypes (estrogen receptor \[ER\], progesterone receptor \[PR\], human epidermal growth factor receptor 2 \[HER2\], etc.) are acceptable * Scheduled to receive neoadjuvant or adjuvant cytotoxic chemotherapy. Patient must be enrolled ≤ 3 weeks from start of cytotoxic chemotherapy * Age 18 to 85 years at enrollment. The upper age cut-off is due to the increased risk of injury in the older population during the CPET, which uses stationary bicycle exercise testing, outweighing the benefit of including this age group * Must be able to complete a stationary bicycle exercise test where you pedal against some resistance on a stationary bike with supervisors at your side per patient self-report * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting per patient self-report * Able to hold breath for 8 seconds * Must be able to read and understand English language * Must have access to a device that allows teleconferencing (e.g., Zoom calls) or be willing to participate in the Tablet Lending Program * Must be willing to download and use the Trainerize application to their personal device or be willing to participate in the Tablet Lending Program * Must have a working email address to participate in teleconferencing (e.g., Zoom calls). Local National Cancer Institute Community Oncology Research Program (NCORP) site staff may assist in setting up a new email address, if needed Exclusion Criteria: * At enrollment, the following diagnosis and/or conditions may not be present (i.e., documented in the medical record or by patient self-report): * Symptomatic claustrophobia * Pregnancy or breast-feeding * Ferromagnetic cerebral aneurysm clips or other intraorbital/intracranial metal; pacemakers, defibrillators, functioning neurostimulator devices or other implanted non-compatible MRI devices, such as tissue expanders * Uncontrolled hypertension (systolic blood pressure \> 190 mm Hg or diastolic blood pressure \> 100 mm Hg) * Inflammatory conditions such as lupus or inflammatory bowel disease, or another medical condition that might compromise safety or successful completion, as determined by the treating physician * Significant ventricular arrhythmias (\> 20 premature ventricular contractions \[PVCs\]/min) * Atrial fibrillation with uncontrolled ventricular response (\> 130 beats per minute \[bpm\]) * Unstable or stable angina (cardiac chest pain) * Severe pulmonary hypertension * Left main coronary artery disease * Symptomatic heart failure * Severe valvular heart disease * Aortic aneurysm (\> 45 mm diameter) or aortic dissection * Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise * Hypertrophic obstructive cardiomyopathy * Acute myocardial infarction within 28 days of enrollment * Acute pulmonary embolus and/or deep vein thrombosis within 24 weeks prior to enrollment * Plans to relocate within 6 months of enrollment and unable to participate in study procedures * May not be on a simultaneous interventional supportive care (non-therapeutic) clinical trial * May not be undergoing simultaneous treatment for a concurrent second primary cancer (patients with historical cancer will not be excluded if chemotherapy was received ≥ 2 years prior) * May not be currently engaged in ≥ 300 minutes of moderate to vigorous intensity physical activity per week as determined by self-report on the International Physical Activity Questionnaire -Short Form (IPAQ-SF). Site should use the IPAQ-SF screener in the REDCap WF-2401 STEPS-BC screening project to assist in this determination
Conditions Adult Congenital Heart Disease, Pulmonar...
Phase Not Applicable
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A repository of biospecimens and detailed phenotypic information collected longitudinally from adults with congenital heart disease and related conditions, with an aim to facilitate future research on biologic mechanisms of underlying disease, compensation and deterioration; biologic correlates of patient experience and functional status; associations between clinical characteristics and various biomarkers; and predictors of clinical outcomes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Successful establishment of biospecimen repository (Day 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-07-01
Completion: 2050-01-01
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: true
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital Medical Center, Cincinnati
Principal Investigators:
  • Sasha Opotowsky (PRINCIPAL_INVESTIGATOR) - Children's Hospital Medical Center, Cincinnati
Contact Information
Study Contact:
Sasha Opotowsky, MD
513-803-2243
sasha.opotowsky@cchmc.org
Lindsay Fist
lindsay.fist@cchmc.org
Interventions
N/A
Study Locations (1 sites)
Children's Hospital Medical Center, Cincinnati, Cincinnati, Ohio 45229 United States
Eligibility Criteria
Inclusion Criteria: 1. Any person ≥ 16 years-old suspected of having or diagnosed with congenital heart disease (CHD), other cardiovascular disease (CVD), pulmonary hypertension, connective tissue disease, or genetic syndrome/diagnosis. 2. Additionally, a cohort (Control group A) of control subjects will be enrolled, again ≥16 years-old, self-reported non-smokers without a known history of diabetes mellitus, myocardial infarction, stroke, heart failure, or chronic kidney disease. These controls will be either: 1. A family member or other person accompanying a patient to a clinical encounter; or, 2. A volunteer recruited via an advertisement; or, 3. Another person who volunteers to enroll in HIBR-ACHD. 3. A cohort (Control group B) of comparison subjects who do not have CHD, but have a diagnosis of heart failure or pulmonary hypertension. Exclusion Criteria: * Unable to provide informed consent/assent personally or via a legal guardian. * Considered unsafe to collect the biospecimen determined by either a clinical provider or an HIBR-ACHD investigator. * Overnight hospitalization for non-obstetric reason with discharge in the prior 30 days.
Conditions Hypertension
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Live Healthy Chicago (LHC) Community Pilot is a prospective, community-based study evaluating the feasibility, effectiveness, and economic impact of a pharmacist-led hypertension management program delivered in trusted community settings on the West and South Sides of Chicago. Adults with uncontrolled hypertension will be identified and enrolled through community-based organizations, where a mobile clinical team-including community health workers, a pharmacist, and a registered nurse-will provide blood pressure screening, medication management, health education, and care coordination over a 3-month period. The study will assess participant engagement and acceptability, changes in systolic blood pressure. This pilot aims to address disparities in hypertension control by improving access to care in underserved communities and informing scalable, community-based models of chronic disease management.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Community-Based Multidisciplinary Hypertension Management Program — A 12-week community-based hypertension management intervention delivered in community settings. The program includes pharmacist-led medication management under collaborative practice agreement, RN-led clinical monitoring and follow-up, and CHW-led outreach, education, and care navigation. Participants receive blood pressure screening, medication titration when indicated, home blood pressure monitoring support, and linkage to primary care and social services.

Primary Outcomes

  • Change in Systolic Blood Pressure (SBP) (Baseline to 3 months (12 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-20
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rush University Medical Center
Principal Investigators:
  • Elizabeth Lynch, PhD (PRINCIPAL_INVESTIGATOR) - Rush University Medical Center
Contact Information
Study Contact:
Elizabeth Lynch, PhD
312-563-2254
Elizabeth_Lynch@rush.edu
Rebecca Dawar, MPH
312-942-8571
Rebecca_Dawar@rush.edu
Elizabeth Lynch, PhD
312-563-2254
Elizabeth_Lynch@rush.edu
Rush University Medical Center
Interventions
  • Behavioral: Community-Based Multidisciplinary Hypertension Management Program — A 12-week community-based hypertension management intervention delivered in community settings. The program includes pharmacist-led medication management under collaborative practice agreement, RN-led clinical monitoring and follow-up, and CHW-led outreach, education, and care navigation. Participants receive blood pressure screening, medication titration when indicated, home blood pressure monitoring support, and linkage to primary care and social services.
Study Locations (1 sites)
Rush University Medical Center, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria: * Adults 18 years or older * Record of two blood pressure readings of SBP\>130 on two separate occasions (days) within the past 3 months Exclusion Criteria: * Person is receiving dialysis * Person has had a heart or kidney transplant * Person is pregnant
Conditions Advanced Unresectable, Metastatic
Phase PHASE1, PHASE2
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker screening, each participant is assigned the best-matched dual-target construct from a predefined target-pair library. The trial is designed to test whether biomarkerguided dual targeting can improve tumor control, reduce antigenescape risk, and preserve safety in solid tumors.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Autologous dual-target CAR-T cells selected from the predefined target library. — Autologous dual-target CAR-T cells are patient-derived T cells engineered to recognize two tumor-associated antigens selected from a predefined target library. In clinical trials, they are administered to enhance tumor targeting and reduce antigen escape, with evaluation of safety, tolerability, and preliminary anti-tumor activity.
  • Drug: Fludarabine — chemotherapy preconditioning regimen used before cell therapy to reduce the patient's existing lymphocytes and create space for infused cells. In clinical trials, it is given prior to CAR-T infusion to enhance cell expansion, persistence, and overall treatment efficacy.
  • Drug: Cyclophosphamide — Cyclophosphamide lymphodepletion is a chemotherapy preconditioning regimen administered prior to cell therapy to suppress existing immune cells and improve the environment for infused cells. In clinical trials, it is given before CAR-T infusion to support cell expansion, persistence, and enhance therapeutic effectiveness.

Primary Outcomes

  • Dose-limiting toxicities (DLTs) (28 Days)
  • Incidence and severity of treatment-emergent adverse events (12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-03-02
Completion: 2028-03-17
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Biotech
Contact Information
Study Contact:
shan S Lu, Phd
+86 13076790030
Seni-Lu@beijing-biotech.com
Zhen J Peng, Phd
+86 13076790039
Zhen-Peng@beijing-biotech.com
Peking University Shenzhen Hospital
Interventions
  • Biological: Autologous dual-target CAR-T cells selected from the predefined target library. — Autologous dual-target CAR-T cells are patient-derived T cells engineered to recognize two tumor-associated antigens selected from a predefined target library. In clinical trials, they are administered to enhance tumor targeting and reduce antigen escape, with evaluation of safety, tolerability, and preliminary anti-tumor activity.
  • Drug: Fludarabine — chemotherapy preconditioning regimen used before cell therapy to reduce the patient's existing lymphocytes and create space for infused cells. In clinical trials, it is given prior to CAR-T infusion to enhance cell expansion, persistence, and overall treatment efficacy.
  • Drug: Cyclophosphamide — Cyclophosphamide lymphodepletion is a chemotherapy preconditioning regimen administered prior to cell therapy to suppress existing immune cells and improve the environment for infused cells. In clinical trials, it is given before CAR-T infusion to support cell expansion, persistence, and enhance therapeutic effectiveness.
Study Locations (1 sites)
Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036 China
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years at consent * Histologically or cytologically confirmed advanced unresectable, metastatic, or recurrent solid malignancy (including recurrent high-grade glioma for CNSspecific pairs) for which standard curative therapy does not exist, is not tolerated, or has failed. * At least one predefined dual-target pair qualifies on central biomarker review. Recommended working thresholds: primary antigen \>= 2+ intensity in \>= 50% of viable tumor cells (or pair-specific equivalent) AND secondary antigen detectable in \>= 25% of viable tumor cells, with acceptable normal-tissue risk after pathology review * At least 1 measurable lesion by RECIST 1.1, or measurable / evaluable disease by RANO for CNS cohorts. * ECOG performance status 0-1 (CNS cohort may allow Karnofsky \>= 70 or ECOG 0-2 if justified). * Adequate organ function: ANC \>= 1.0 x 10\^9/L, platelets \>= 75 x 10\^9/L, hemoglobin \>= 8 g/dL, creatinine clearance \>= 50 mL/min, AST / ALT \<= 3 x ULN (\<= 5 x ULN if liver involvement), total bilirubin \<= 1.5 x ULN unless Gilbert syndrome, LVEF \>= 45%, oxygen saturation \>= 92% on room air. * Recovered to Grade \<= 1 from acute toxicities of prior anticancer therapy (except alopecia, stable endocrinopathies, or other protocol-allowed residual toxicities). * Adequate venous access and ability to undergo leukapheresis; successful manufacture of a release-qualified autologous dual-target CAR-T product. * Life expectancy \>= 12 weeks. * Negative pregnancy test for persons of childbearing potential and agreement to use highly effective contraception per protocol. * Ability to understand and sign informed consent and comply with study follow-up, including long-term gene-modified cell monitoring. Exclusion Criteria: * No qualifying target pair after central review, or target pair considered unsafe because of unacceptable predicted ontarget / off-tumor risk. * Prior gene-modified cellular therapy directed against the same target pair within 6 months, or persistent clinically significant toxicity from prior cell / gene therapy. * Active uncontrolled infection, including uncontrolled bacterial, fungal, or viral infection; active tuberculosis; uncontrolled HIV; active hepatitis B or C with detectable / unsafe viral burden. * Need for systemic corticosteroids \> 10 mg prednisone equivalent daily or other systemic immunosuppressive therapy within 7 days before lymphodepletion, unless specifically allowed for physiologic replacement or CNS edema management per cohort rules. * Active autoimmune disease requiring systemic immunosuppression within the past 2 years, except protocol-allowed stable conditions. * Clinically significant cardiovascular disease (for example uncontrolled arrhythmia, recent myocardial infarction, unstable angina, decompensated heart failure), severe pulmonary compromise, or other major comorbidity making cell therapy unsafe. * Active symptomatic CNS hemorrhage, uncontrolled seizures, or uncontrolled intracranial hypertension; leptomeningeal disease requiring urgent intervention unless explicitly allowed in a CNS-specific cohort. * Pregnancy or breastfeeding. * Concurrent second malignancy requiring active systemic treatment, except certain low-risk or definitively treated cancers allowed by protocol. * Any condition that, in the investigator's judgment, would interfere with safe participation, product manufacture, infusion, or interpretation of results.
Conditions Breast Cancer, Bone Marrow Suppression
Phase PHASE4
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The subjects were randomly assigned to Group A or Group B in a 1:1 ratio, stratified by early/late stage. Group A: In the first cycle, they took Shengbai Oral Liquid (40 ml, three times a day), and in the second cycle, they took Leucogen Tablets (20 mg, three times a day). Group B: In the first cycle, they took Leucogen Tablets (20 mg, three times a day), and in the second cycle, they took Shengbai Oral Liquid (40 ml, three times a day).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Group A — In the first cycle, they took Shengbai Oral Liquid (40 ml, three times a day), and in the second cycle, they took Leucogen Tablets (20 mg, three times a day).
  • Drug: Group B — In the first cycle, they took Leucogen Tablets (20 mg, three times a day), and in the second cycle, they took Shengbai Oral Liquid (40 ml, three times a day).

Primary Outcomes

  • Lowest neutrophil count (ANC) in the two stages (From the initial treatment to the end of follow-up, approximately 42 or 56 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-08-06
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hongxia Wang
Contact Information
Study Contact:
Hongxia wang, PhD
021-64175590
whx365@126.com
Interventions
  • Drug: Group A — In the first cycle, they took Shengbai Oral Liquid (40 ml, three times a day), and in the second cycle, they took Leucogen Tablets (20 mg, three times a day).
  • Drug: Group B — In the first cycle, they took Leucogen Tablets (20 mg, three times a day), and in the second cycle, they took Shengbai Oral Liquid (40 ml, three times a day).
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Age range: 18 to 80 years old, gender unrestricted; 2. Patients with breast cancer confirmed by histopathology. 3. ECOG performance status score ≤ 2; expected survival time ≥ 12 weeks; 4. During the period of anti-tumor drug treatment before enrollment (including but not limited to chemotherapy drugs: paclitaxel, capecitabine, vinorelbine; CDK4/6 inhibitors: palbociclib, dalpiciclib, ribociclib, abemaciclib; antibody-drug conjugates: trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, larotrectinib), grade II-III neutropenia occurred, and it is planned to continue the original treatment plan and dose for at least 2 cycles. 5. The subject meets the criteria for continuing anti-tumor drug treatment; normal bone marrow hematopoietic function, no bleeding tendency (INR \< 1.5); blood routine meets the following requirements: Hb ≥ 8g/dl, platelet count ≥ 75×109/L; liver and kidney function meets the following requirements: AST and ALT ≤ 3 ULN, total bilirubin ≤ 2 ULN, serum creatinine ≤ 1.5 ULN; no obvious heart and lung function disorders; 6. The subject has high compliance and voluntarily signs the informed consent form. Exclusion Criteria: * 1\. Having participated in other new drug clinical trials within 4 weeks before enrollment; planning to participate in other new drug clinical trials during the study period; planning to add other anti-tumor treatments during the study period; 2. Having received bone marrow radiotherapy involving 25% of the bone marrow; having undergone hematopoietic stem cell transplantation or bone marrow transplantation; 3. Uncontrolled acute or chronic infection; having severe underlying diseases such as heart, lung, liver or kidney diseases; having primary diseases of the hematopoietic system; having diseases such as hypersplenism, hyperthyroidism, adrenal insufficiency, connective tissue diseases, etc. that can cause a decrease in white blood cells; 4. Uncontrolled digestive system symptoms that affect the administration of the study drug; confirmed or suspected allergy to the study drug or its related components; 5. Uncontrolled psychological or mental disorders; judged by the investigator as unsuitable for participation in this study.
Conditions Depressive Disorder (Per DSM-V Criteria,...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, controlled study. ACS follow- up patients aged 18 to 80 years old with hemodynamic stability, who are 14 days to 1 year after PCI, are screened through the HAMD score and the HAMA score. Patients with a HAMD score greater than 7 points and a HAMD score higher than that of the HAMA, are included in this study. Patients were allocated to the active taVNS group or sham taVNS group with a 1:1 ratio. Both groups received the stimulation for 20 minutes each time, twice a day with an 8-week treatment and a 8-week follow-up. All treatments were self-administered by the patients at home after they received training from the hospitals. The primary observation endpoints include the depression scores of the HAMD. The secondary observation endpoints include the HAMA 、GAD、 response and remission rates of HAMD ,as well as the PCL-C for post-traumatic stress disorder. We also observed the cardiac function indexes measured by echocardiography and the B-type natriuretic peptide .

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Intervention — Transcutaneous auricular vagus nerve stimulation (taVNS) is delivered to the cymba conchae of the ear using a dedicated stimulator device, with parameters set as 20 Hz frequency, 0.5-3mA intensity, 20 minutes per session, twice daily for 8 weeks.
  • Device: sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Control — sham Transcutaneous Auricular Vagus Nerve Stimulation Control treatment with the same device of active stimulation group, wearing method, and parameter adjustments as active stimulation group However, stimulation will only be delivered for the first 5 seconds, with no subsequent electrical output. Treatment frequency will be identical to that of active stimulation group.

Primary Outcomes

  • Change in depressive symptom severity as measured by the 17-item Hamilton Depression Rating Scale (HAMD-17) from baseline (Week 0) to Week 8 (from baseline (Week 0) to Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-06
Completion: 2026-08-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jing Han
Principal Investigators:
  • wangang Guo, Doctor of Philosophy (PRINCIPAL_INVESTIGATOR) - Department of Cardiology,Tang-Du Hospital
Contact Information
Study Contact:
jing Han, Pursuing Master's Degree
8618506576253
710694996@qq.com
wangang Guo, Doctor of Philosophy
8618629581753
Guowagon@qq.com
Wangang Guo, Doctor of Philosophy
8618629581753
Guowagon@qq.com
Tang-Du Hospital,Department of Cardiology
Interventions
  • Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Intervention — Transcutaneous auricular vagus nerve stimulation (taVNS) is delivered to the cymba conchae of the ear using a dedicated stimulator device, with parameters set as 20 Hz frequency, 0.5-3mA intensity, 20 minutes per session, twice daily for 8 weeks.
  • Device: sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Control — sham Transcutaneous Auricular Vagus Nerve Stimulation Control treatment with the same device of active stimulation group, wearing method, and parameter adjustments as active stimulation group However, stimulation will only be delivered for the first 5 seconds, with no subsequent electrical output. Treatment frequency will be identical to that of active stimulation group.
Study Locations (1 sites)
Tang-Du Hospital,Department of Cardiology, Xi'an, Shaanxi 710038 China
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Meeting the diagnostic criteria for ACS * 14 days to 12 months after successful PCI, with stable vital signs * Meeting the diagnostic criteria for depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * HAMD-17 score ≥7 and \<24 (mild-to-moderate depression), with HAMA score \<HAMD score; * Refusal of psychiatric consultation, antidepressant medication, or psychological therapy by the patient or their legal representative after full informed consent * Voluntary participation in the study and signing of the informed consent form Exclusion Criteria: * Severe heart failure (New York Heart Association \[NYHA\] class ≥III) * Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and diastolic blood pressure ≥110 mmHg) * Electrocardiographic abnormalities (first-degree atrioventricular block with PR interval ≥0.20 s, second-degree type II or third-degree atrioventricular block at any time, 24-hour average heart rate ≤50 beats per minute, RR interval ≥3 s) or a history of syncope unrelated to the current ACS * Dialysis-dependent patients * Previous renal sympathetic denervation or vagal ganglion ablation * Expected survival time \<4 months * Pre-PCI diagnosis of severe mental illnesses, including schizophrenia, severe intellectual disability, or substance abuse * Current use of antipsychotic medications * High suicide risk * Pregnant or lactating women * Left ear diseases, acute exacerbation of asthma or chronic obstructive pulmonary disease, or other conditions precluding taVNS treatment * Implanted cardiac pacemaker, implantable cardioverter-defibrillator (ICD), or other implantable stimulators (e.g., vagus nerve stimulator, deep brain stimulator)
Conditions Hemodialysis Complication, Hemodialysis
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the effects of progressive muscle relaxation exercises on depression and fatigue levels in patients undergoing hemodialysis treatment. Progressive muscle relaxation is applied as an individualized non-pharmacological intervention, and its potential contribution to psychological well-being is investigated. The study seeks to determine whether regular relaxation exercises can reduce depressive symptoms, alleviate fatigue, and improve overall emotional well-being in hemodialysis patients. Findings from this research are expected to provide evidence for the use of relaxation-based interventions as supportive care methods in the management of psychological symptoms associated with chronic kidney disease and hemodialysis.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Progressive Muscle Relaxation Intervention — The study population consisted of all patients receiving treatment at the center during the study period. Instead of a statistical sample size calculation, a total population sampling method was used. All voluntary patients who met the inclusion criteria and were receiving hemodialysis at the center during the specified time frame were included. Among patients who scored 4 or above on the First-Level Beck Depression Inventory, an independent nurse not involved in the research team assigned unique codes. A computer-generated random number table was then used to allocate participants into the intervention group (30 patients) and control group (30 patients) in a 1:1 ratio.Progressive muscle relaxation exercises were used as the relaxation technique. Participants were instructed to assume a comfortable position, and all instructions were delivered clearly and understandably. The exercise program was planned for 8 weeks, 3 days per week, for 30 minutes per session. The first session was con

Primary Outcomes

  • First-Level Beck Depression Screening Inventory (BDÖ-BB): (12 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-01
Completion: 2026-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul Aydın University
Contact Information
Study Contact:
ARZU KAVALA, Assistant Prof
+905445418208
arzukavala@aydin.edu.tr
Arzu Kavala, Assistant Prof
+905445418208
arzukavala@aydin.edu.tr
Istanbul Aydın Universty
Arzu Kavala
+905445418208
Arzu Kavala
Interventions
  • Behavioral: Progressive Muscle Relaxation Intervention — The study population consisted of all patients receiving treatment at the center during the study period. Instead of a statistical sample size calculation, a total population sampling method was used. All voluntary patients who met the inclusion criteria and were receiving hemodialysis at the center during the specified time frame were included. Among patients who scored 4 or above on the First-Level Beck Depression Inventory, an independent nurse not involved in the research team assigned unique codes. A computer-generated random number table was then used to allocate participants into the intervention group (30 patients) and control group (30 patients) in a 1:1 ratio.Progressive muscle relaxation exercises were used as the relaxation technique. Participants were instructed to assume a comfortable position, and all instructions were delivered clearly and understandably. The exercise program was planned for 8 weeks, 3 days per week, for 30 minutes per session. The first session was con
Study Locations (2 sites)
Istanbul Aydın Universty, Istanbul, Istanbul Turkey (Türkiye)
Arzu Kavala, Istanbul, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: Scoring 4 or above on the First-Level Beck Depression Inventory Patients who regularly receive hemodialysis treatment Individuals who are cognitively capable of understanding the exercise instructions Individuals who voluntarily agree to participate in the study and provide informed consent Exclusion Criteria: Individuals diagnosed with a psychiatric disorder (e.g., major depression, bipolar disorder, schizophrenia, etc.) Individuals who are physically unable to perform relaxation exercises due to musculoskeletal disorders Individuals who have previously participated regularly in relaxation therapy, yoga, meditation, or similar practices Individuals who cannot follow instructions due to hearing, visual, or cognitive impairments Individuals who are simultaneously participating in another psychosocial or physical intervention program \-

SnapDandCGMinType2DM

NCT07533604
Recruiting
Conditions Type2 Diabetes Mellitus
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Study Title: The Effectiveness of an AI-powered Thai food analysis (SnapD) and Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes and Overweight or Obesity: A Randomized Controlled Pilot Study Rationale: Effective dietary management is the cornerstone of treating Type 2 Diabetes (T2DM) and obesity. However, traditional manual food logging is often inaccurate and burdensome. While digital tools and Continuous Glucose Monitoring (CGM) have shown promise internationally, there is a lack of validated AI-powered tools specifically designed for Thai cuisine. This study introduces SnapD, an AI-powered platform (utilizing Gemini 2.5 Flash) designed to recognize Thai food, estimate nutritional values, and integrate with CGM data to provide personalized feedback. The primary goal of this pilot study is to evaluate the efficacy of the SnapD application, both as a standalone tool and in combination with CGM, compared to Standard of Care in improving glycemic control (HbA1c) over 8 weeks. Additionally, the study aims to assess the feasibility, participant adherence, and safety of these digital interventions to inform a future, fully powered randomized controlled trial. Study Design: This is an 8-week, randomized, open-label, parallel-group, superiority pilot study with a 1:1:1 allocation ratio. A total of 45 participants will be enrolled and assigned to one of three arms: 1. Intervention Arm 1: SnapD application + Real-time CGM + Diabetes Self-Management Education and Support (DSMES) 2. Intervention Arm 2: SnapD application standalone + DSMES 3. Control Arm: DSMES alone Inclusion Criteria Highlights: Adults (18-65 years) diagnosed with T2D with BMI \> 23 kg/m² (overweight/obesity) with HbA1c between 6.5% and 9.0% with Must possess a compatible smartphone/tablet Procedures: Baseline (Visit 1): All participants receive 20-30 minutes of DSMES. Intervention groups receive training on SnapD. Arm 1 receives a 15-day CGM sensor.During Study: Intervention arms log meals via SnapD (at least twice daily). Nutritionists conduct bi-weekly follow-up calls to address technical issues and provide support. End-of-Study (Week 8): Assessment of HbA1c, body weight, waist circumference, lipid profile, and patient-reported outcomes (self-care activities and user satisfaction) Primary Outcome: Mean change in HbA1c from baseline to 8 weeks Secondary Outcomes: Changes in Fasting Plasma Glucose (FPG), body weight, waist circumference, and lipid profiles, Diabetes self-management scores (SDSCA questionnaire), User satisfaction with the SnapD application, Incidence of adverse events (hypoglycemia/hyperglycemia). Significance: This study will provide preliminary evidence on the synergistic benefits of AI-driven nutritional feedback and CGM in a Thai-specific context, supporting the development of scalable, culturally adapted digital health technologies for diabetes management.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: SnapD — SnapD, developed by the Division of Endocrinology and Metabolism, Department of Medicine, Ramathibodi Hospital, is a Progressive Web App. It is built using React 18.3.1, TypeScript, and Vite for responsive performance on both mobile and desktop platforms. The application utilizes Supabase for database management, which operates on a PostgreSQL backend.
  • Device: Linx CGM — The Linx CGM system, manufactured by Connect Diagnostics, is a real-time device that measures glucose concentrations in the interstitial fluid. It is an all-in-one device, integrating the glucose sensor, applicator, and transmitter into a single unit. The device has a diameter not exceeding 22 mm and a weight not exceeding 2.2 g. The sensor has a maximum operational life (wear time) of 15 days. It demonstrates a Mean Absolute Relative Difference (MARD) not exceeding 8.67%, which meets the standard accuracy requirement of \<10%. This device was registered as a medical device by the Thai Food and Drug Administration (Thai FDA), Ministry of Public Health, in January 2025, for the indication of management of diabetes in adults age 18 and older (as shown in the attached document) .
  • Other: Diabetes Self-Management Education (DSMES) — Participants will receive 1 single session of DSMES, 20-30 minutes/session. This single session will be delivered at the baseline visit only. All personnel providing DSMES are Certified Dietitians (CD) and/or have passed the Certified Diabetes Educator (Thai CDE) examination

Primary Outcomes

  • To evaluate the efficacy of two intervention arms on glycemic control (baseline, 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-20
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ramathibodi Hospital
Principal Investigators:
  • Supasuta Wongdama (PRINCIPAL_INVESTIGATOR) - Ramathibodi Hospital
Contact Information
Study Contact:
Supasuta Wongdama, MD
+6690-575-4190
supasuta.won@gmail.com
Supasuta Wongdama, Doctor of Medicine
+6690-575-4190
supasuta.won@gmail.com
Department of Medicine, Ramathibodi Hospital,
Interventions
  • Device: SnapD — SnapD, developed by the Division of Endocrinology and Metabolism, Department of Medicine, Ramathibodi Hospital, is a Progressive Web App. It is built using React 18.3.1, TypeScript, and Vite for responsive performance on both mobile and desktop platforms. The application utilizes Supabase for database management, which operates on a PostgreSQL backend.
  • Device: Linx CGM — The Linx CGM system, manufactured by Connect Diagnostics, is a real-time device that measures glucose concentrations in the interstitial fluid. It is an all-in-one device, integrating the glucose sensor, applicator, and transmitter into a single unit. The device has a diameter not exceeding 22 mm and a weight not exceeding 2.2 g. The sensor has a maximum operational life (wear time) of 15 days. It demonstrates a Mean Absolute Relative Difference (MARD) not exceeding 8.67%, which meets the standard accuracy requirement of \<10%. This device was registered as a medical device by the Thai Food and Drug Administration (Thai FDA), Ministry of Public Health, in January 2025, for the indication of management of diabetes in adults age 18 and older (as shown in the attached document) .
  • Other: Diabetes Self-Management Education (DSMES) — Participants will receive 1 single session of DSMES, 20-30 minutes/session. This single session will be delivered at the baseline visit only. All personnel providing DSMES are Certified Dietitians (CD) and/or have passed the Certified Diabetes Educator (Thai CDE) examination
Study Locations (1 sites)
Department of Medicine, Ramathibodi Hospital,, Bangkok, Bangkok 10400 Thailand
Eligibility Criteria
Inclusion Criteria: 1. Aged 18 to 65 years, male or female at birth 2. Diagnosed with type 2 Diabetes Mellitus with overweight or obesity (BMI\>23 kg/m²) 3. Hemoglobin A1c (HbA1c) 6.5-9% measured within 3 months prior to the screening date 4. Willing to maintain their current antidiabetic medication regimen without dose adjustment for the entire 8-week study duration 5. Must possess an internet-enabled devices e.g. smartphone, tablet compatible with the SnapD application 6. Able and willing to adhere intervention, including using snapD and CGM Exclusion Criteria: 1. Currently pregnant, plan pregnancy or breastfeeding during the 8-week study period 2. Current participation in another interventional clinical trial 3. Current use of insulin or incretin-based therapies (e.g., GLP-1 Receptor Agonists, GIP/GLP-1 Receptor Agonists) 4. Presence of severe hearing or visual impairment that, in the investigator's judgment, would preclude the participant from safely and effectively using the SnapD application or the CGM device 5. known contraindication to CGM usage e.g., a history of severe hypersensitivity to the device's materials or adhesive, planing to go on CT-contrasted imaging etc.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 69
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The PRIMROSE CSF Study aims to study cerebrospinal fluid (CSF) in patients with breast cancer that has spread to the brain (brain metastasis) or the lining surrounding the brain (leptomeningeal disease). Research into breast cancer that has spread to the brain or the lining of the brain is limited due to difficulty in obtaining brain tissue containing cancer cells. Such tissue is typically only available when tumours are removed, which does not occur in all patients. Evidence indicates an increasing number of patients with breast cancer are developing disease that spreads to the brain or the lining of the brain as treatments improve. The PRIMROSE CSF Study aims to improve understanding of breast cancers that spread to the brain or brain lining by collecting and analysing the fluid that circulates around the brain and comparing these samples with other cancer and blood samples. Cancer cells that have spread to the brain or its lining shed genetic material into the surrounding fluid. Collection of this fluid enables purification of genetic material released by breast cancer cells. This approach allows examination of the genetic profile of breast cancer cells affecting the brain or its lining without the need for surgery. Differences between the original cancer and metastatic disease in the brain can then be analysed. This research will support improved understanding of why certain breast cancers spread to the brain and contribute to the development of new treatments for breast cancer that has spread to the brain or the lining of the brain.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Primary Outcome (Up to 2 years post randomisation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-01
Completion: 2035-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 69 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal College of Surgeons, Ireland
Contact Information
Study Contact:
Leonie Young, PhD
breastcancerbank@rcsi.ie
breastcancerbank@rcsi.ie
Interventions
N/A
Study Locations (1 sites)
Beaumont RCSI Cancer Centre, Dublin, Ireland
Eligibility Criteria
Inclusion Criteria: 1. Male or female. 2. \>18 years of age 3. Any ER, PgR or HER2 status 4. Newly diagnosed with Breast Cancer Brain Metastasis (BCBM) OR Progressive BCBM following either local or systemic treatment OR Leptomeningeal disease 5. Informed Consent Exclusion Criteria: 1. Where the investigator considers it unsafe to undertake a lumbar puncture or perform an aspiration from the Ommaya reservoir. 2. Unable to comply with study procedures or give informed consent. 3. Where the investigator considers it not in the best interest of the patient to participate.
Conditions Asthma
Phase PHASE2
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the effect of L-menthol on breathlessness and exercise capacity in patients with Asthma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: L-menthol — (Sigma-Aldrich, St. Louis, US)
  • Other: Placebo — Strawberry scent (Sigma-Aldrich, St. Louis, US)

Primary Outcomes

  • Breathlessness intensity (During submaximal test, at isotime during day 2 and day 3.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-07
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Skane
Collaborators: Blekinge Institute of Technology, Blekingesjukhuset, Karlskrona
Contact Information
Study Contact:
Zainab Ahmadi, MD, PhD
046171000
zainab.ahmadi@med.lu.se
Jacob Sandberg, MD, PhD
+46 (0)455-38 54 09
jacob.sandberg@bth.se
Blekinge Institute of Technology
Zainab Ahmadi, MD, PhD
046171000
zainab.ahmadi@med.lu.se
Lund University hospital and Region Skåne
Interventions
  • Drug: L-menthol — (Sigma-Aldrich, St. Louis, US)
  • Other: Placebo — Strawberry scent (Sigma-Aldrich, St. Louis, US)
Study Locations (2 sites)
Blekinge Institute of Technology, Karlskrona, Blekinge County Sweden
Lund University hospital and Region Skåne, Lund, Sweden
Eligibility Criteria
Inclusion Criteria: * the subject has given written consent to participate in the study * physician diagnosis of Asthma according to international guidelines * mMRC (modified Medical Research Council) score of 1 or above * age 18 years or older * able to cycle * able to understand and talk Swedish to participate in the study procedures, as judged by the Investigators. Exclusion Criteria: * resting peripheral oxygen saturation (SpO2) \< 92% * hospitalization or clinical instability during the last four weeks * treatment with supplementary oxygen at rest or during exercise * contraindication to exercise testing in accordance with clinical practice guidelines * expected survival shorter than six months as judged by the Investigator * medical conditions including congestive heart failure, acute coronary artery disease, neuromuscular diseases, severe psychiatric illness, and olfaction disorder.
Conditions Asthma
Phase PHASE3
Enrollment 554
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a study comparing CHF 5993 pMDI HFA-152a with CHF 1535 pMDI HFA-134a in Chinese patients with asthma uncontrolled on medium doses of ICS+LABA.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Experimental: Participant Group CHF 5993 pMDI HFA-152a — total daily dose of BDP/FF/GB:400/24/50 μg Administration: Two (2) inhalations twice daily(BID) (i.e., 2 inhalations in the morning and 2 inhalations in the evening), total daily dose of BDP/FF/GB: 400/24/50 μg (subjects used to inhaling their asthma pMDI medications with a spacer should continue using the spacer AeroChamber Plus Flow Vu AntiStaticTM to take the pMDI study treatments)
  • Other: Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a — total daily dose of BDP/FF: 400/24 μg Administration: Two (2) inhalations BID (i.e., 2 inhalations in the morning and 2 inhalations in the evening), total daily dose of BDP/FF: 400/24 μg (subjects used to inhaling their asthma pMDI medications with a spacer should continue using the spacer AeroChamber Plus Flow Vu Anti-StaticTM to take the pMDI study treatments).

Primary Outcomes

  • Peak FEV1 (At week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-06-26
Completion: 2028-10-17
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 554 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chiesi Farmaceutici S.p.A.
Principal Investigators:
  • Chen Wang Academician, Principal Investigator (PRINCIPAL_INVESTIGATOR) - China-Japan Friendship Hospital
Contact Information
Study Contact:
Clinical Trial INFO Chiesi Farmaceutici S.p.A.
+ 39 0521 2791
clinicaltrials_info@chiesi.com
Chen Wang, Academician
+86 -10 -84205288
China-Japan Friendship Hospital
Chen Wang, Academician
China-Japan Friendship Hospital
Interventions
  • Drug: Experimental: Participant Group CHF 5993 pMDI HFA-152a — total daily dose of BDP/FF/GB:400/24/50 μg Administration: Two (2) inhalations twice daily(BID) (i.e., 2 inhalations in the morning and 2 inhalations in the evening), total daily dose of BDP/FF/GB: 400/24/50 μg (subjects used to inhaling their asthma pMDI medications with a spacer should continue using the spacer AeroChamber Plus Flow Vu AntiStaticTM to take the pMDI study treatments)
  • Other: Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a — total daily dose of BDP/FF: 400/24 μg Administration: Two (2) inhalations BID (i.e., 2 inhalations in the morning and 2 inhalations in the evening), total daily dose of BDP/FF: 400/24 μg (subjects used to inhaling their asthma pMDI medications with a spacer should continue using the spacer AeroChamber Plus Flow Vu Anti-StaticTM to take the pMDI study treatments).
Study Locations (2 sites)
China-Japan Friendship Hospital, Beijing, Chaoyang District China
China-Japan Friendship Hospital, Beijing, Chaoyang District China
Eligibility Criteria
Inclusion Criteria: * Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the study: 1. Subjects must provide written informed consent prior to any study-related procedures; 2. Subjects must be male or female Chinese aged ≥18 and ≤75 years; 3. Subjects must have a documented history of asthma for at least 1 year and asthma must have been diagnosed before the subject's age of 40; 4. Subjects must have uncontrolled asthma, receiving double therapy only on medium doses of ICS in combination with LABA at a stable dose for at least 4 weeks prior to screening; 5. Subjects must have a pre-bronchodilator FEV1 \<80% of their predicted normal value, after appropriate wash out from bronchodilators at the screening visit. 6. Subjects must have a positive response to a reversibility test at screening. 7. Subjects must have uncontrolled asthma evidenced by a score at the ACQ-7 ≥1.5 (this criterion must be met at screening and at randomisation). Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from study enrolment: 1. Subjects who have a history of near fatal asthma or of a past hospitalisation for status asthmaticus or severe asthma exacerbation which, in the judgement of the Investigator, may place the subject at undue risk; 2. Subjects who have undergone hospitalisation, emergency room visit or use of systemic corticosteroids for an asthma exacerbation in the 4 weeks prior to the screening visit or during the run-in period; 3. Subjects with any asthma exacerbation or respiratory tract infection in the 4 weeks prior to the screening visit or during run-in period; 4. Subjects with any change in dose, schedule or formulation of the combination ICS+LABA in the 4 weeks prior to the screening visit; 5. Subjects who have used systemic corticosteroid medication in the 4 weeks prior to screening or slow-release corticosteroids in the 12 weeks prior to screening; 6. Subjects who have a history of a diagnosis of chronic obstructive pulmonary disease (COPD) (according to the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] document), cystic fibrosis, bronchiectasis or alpha- 1 antitrypsin deficiency or any other significant lung disease which may interfere with study evaluations; 7. Subjects who are current smokers; ex-smokers with total cumulative exposure ≥10 pack-years; having stopped smoking 1 year or less prior to the screening visit; 8. Subjects who are treated with monoclonal antibodies (e.g., anti-immunoglobulin (Ig)E or anti-IgG antibodies) or biological drugs; 9. Subjects who have received an investigational drug within 2 months or six half-lives (whichever is greater) prior to the screening visit, or have been previously randomised in this study, or are currently participating in another clinical study.